The Korean Cannabinoid Association (KCA) said at a conference in Seoul on Monday that it intended to initiate a project to carry out clinical pilots related to cannabidiol (CBD), a constituent of cannabis that is used in multiple sclerosis and epilepsy therapies among others. The KCA will launch the project via Prasm, a decentralized bioinformatic network that leverages artificial intelligence (AI) and blockchain technologies.
Kwon Yong-hyun, director of Prasm and president of the KCA, commented on the project:
“Due to the prejudice that hemp is a drug, Korean medical society has been reluctant to conduct any clinical studies that could prove the therapeutic benefits of medical hemp.”
“We are aware that the majority of the public is concern...
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.